AriBio Co., Ltd. is set to become the first South Korean pharma firm to begin a global Phase III clinical development program for a novel drug for Alzheimer’s disease (AD), following an IND approval from the domestic Ministry of Food and Drug Safety for the Polaris-AD study.
The multinational Phase III trial with the small molecule PDE5 inhibitor AR1001 is set to progress in the US, Europe and China, as well as South Korea, with a goal to recruit a total of 1,250 patients,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?